Inflammatory processes and Alzheimer's disease

Expert Review of Neurotherapeutics

Volumn 4, Issue 5, 2004, Pages 793-798

  Walsh, Sally ^a   Aisen, Paul S ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

amyloid; Alzheimer's disease; Anti inflammatory drugs; Inflammatory hypothesis; Microglia; Senile plaque

Indexed keywords

AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; CELECOXIB; COMPLEMENT COMPONENT C5A; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DICLOFENAC; HYDROXYCHLOROQUINE; INDOMETACIN; INTERLEUKIN 1; INTERLEUKIN 6; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; ROFECOXIB; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; ENZYME INHIBITION; HUMAN; INFLAMMATION; REVIEW; SYSTEMATIC REVIEW;

ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS; EXPERT TESTIMONY; HUMANS; INFLAMMATION;

EID: 4444226059     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.4.5.793     Document Type: Review

References (48)

1. Graeber MB, Kosel S, Moller HJ et al. Histopathology and APOE genotype of the first Alzheimer's disease patient, Auguste D. Neurogenetics 1(3), 223-228 (1998).
2. Aisen PS. Inflammation and Alzheimer's disease: mechanisms and therapeutic strategies. Gerontology 43, 143-149 (1997).
3. Masters CL, Beyreuther K. Alzheimer's disease. Br. Med. J. 316, 446-448 (1998).
4. Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399, A23-A31 (1999).
5. Eikelenboom P, Veerhuis R. The importance of inflammatory mechanisms for the development of Alzheimer's disease. Exp. Gerontol. 34, 453-461 (1999).
6. Akiyama H, Barger S, Barnum S et al. Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421 (2000).
7. Rogers J, Copper NR, Webster S et al. Complement activation by β-amyloid in Alzheimer's disease. Proc. Natl Acad. Sci. USA 89, 10016-10020 (1992).
8. Campbell IL, Abraham CR, Masliah E et al. Neurologic disease induced in transgenic mice by cerebral over expression of interleukin-6. Proc. Natl Acad. Sci. USA 90, 10061-10065 (1993).
9. Anthony JC, Breitner JC, Zandi PP et al. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology 54, 2066-2071 (2000).
10. Aisen PS. The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurology 1, 279-284 (2002).
11. McGeer EG, McGeer PL. Innate immunity in Alzheimer's disease: a model for local inflammatory reactions. Molecular Interventions 1, 22-29 (2001).
12. Bales KR, Du Y, Holtzman D et al. Neuroinflammation and Alzheimer's disease: critical role for cytokine/Aβ induced glial activation, NF-κB, and apolipoprotein E. Neurobiol. Aging 21, 427-432 (2000).
13. Giulian D. Micoglia and the immune pathology of Alzheimer's disease. Am. J. Hum. Genet. 65, 13-18 (1999).
14. Grimaldi LM, Casadei VM, Ferri C et al. Association of early onset Alzheimer's disease with an interleukin-1-α gene polymorphism. Ann. Neurol. 47, 361-365 (2000).
15. Cagnin A, Brooks DJ, Kennedy AM et al. In vivo measurement of activated microglia in dementia. Lancet 358, 461-467 (2001).
16. Giulian D, Li J, Leara B et al. Phagocytic microglia release cytokines and cytotoxins that regulate the survival of astrocytes and neurons in culture. Neurochem. Int. 25, 227-233 (1994).
17. Hull M, Lieb K, Fiebich BL. Pathways of inflammatory activation in Alzheimer's disease: potential targets for disease modifying drugs. Curr. Med. Chem. 9, 83-88 (2002).
18. Groul DL, Nelson TE. Physiological and pathological roles of IL-6 in the central nervous system. Mol. Neurobiol. 25, 227-233 (1997).
19. Venters HD, Tang Q, Liu Q et al. A new mechanism of neurodegeneration: a proinflammatory cytokine inhibits receptor signaling by a survival peptide. Proc. Natl Acad. Sci. 96, 9879-9884 (1999).
20. Mukherjee P, Pasinetti GM. Complement anaphylatoxin C5a neuroprotects through mitogen activated protein kinase-dependent inhibition of capase 3. J. Neurochem. 77, 43-49 (2001).
21. Wyss-Coray T, Lin C, Yan F et al. TGF-β 1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice. Nature Med. 7, 612-618 (1996).
22. Kakimura J, Kitamura Y, Takara K et al. Micoglial activation and amyloid-β clearance induced by exogenous heat-shock protein. FASEB J. 16, 601-603 (2002).
23. Schenk D, Barbour R, Dunn W et al. Immunization with amyloid-β attenuates Alzheimer's - disease-like pathology in the PDAPP mouse. Nature 400, 173-177 (1999).
24. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47, 425-432 (1996).
25. Breitner JC, Gau BA, Welsh KA et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a control study. Neurology 44, 227-232 (1994).
26. Breitner J, Welsh KA, Helms MJ et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol. Aging 16, 523-530 (1995).
27. Stewart WF, Kawas C, Corrada M et al. Risk of Alzheimer's disease and duration of NSAID use. Neurology 48, 626-632 (1997).
28. Anthony JC, Breitner JC, Zandi PP et al. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology 54, 2066-2071 (2000).
29. Henderson AS, Jorm AF, Christensen H et al. Aspirin, anti-inflammatory drugs and risk of dementia. Int. J. Geriatric Psych. 12, 926-930 (1997).
30. Wolfson C, Perrault A, Moride Y et al. A case control analysis of nonsteroidal anti-inflammatory drugs and Alzheimer's disease: are they protective? Neuroepidemiology 21, 81-86 (2002).
31. Beard CM, Waring SC, O'Brein PC et al. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case control study in Rochester, Minnesota. Mayo Clin. Proc. 73, 951-955 (1998).
32. in t' Veld BA, Ruitenberg A, Hofman A et al. Nonsteroidal inflammatory use and the risk of Alzheimer's disease. N. Engl. J. Med. 345, 1515-1521 (2000).
33. Rogers J, Kirby LC, Hempleman SR et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 43, 1609-1611 (1993).
34. Scharf S, Mander A, Ugoni A et al. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 53, 197-201 (1999).
35. Aisen PS, Davis KL, Berg JD et al. A randomized controlled trial of prednisone in Alzheimer's disease. Neurology 54, 588-593 (2000).
36. Van Gool WA, Weinstein HC, Scheltens PK et al. Effect of hydroxycholoroquine on the progression of dementia in early Alzheimer's disease: an 18 month randomized, double-blind, placebo-controlled study. Lancet 358, 455-460 (2001).
37. Sainati SM, Ingram DM, Talwalker S et al. Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease. Proceeding of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer's Disease. Stockholm, Sweden, 180 (2000).
38. Aisen PS, Marin D, Altstiel L et al. A pilot study of prednisone in Alzheimer's disease. Dementia 7, 201-206 (1996).
39. Sperber K, Quraishi H, Kalb TH et al. Selective regulation of cytokine secretion by hydroxychloroquine: Inhibition of interleukin-1-α and IL-6 in human monocytes and T-cells. J. Rheumatol. 20, 803-808 (1993).
40. Hoozemans JJ, Veerhuis R, Janssen I et al. The role of cyclo-oxygenase 1 and 2 activity in prostaglandin E20 secretion by cultured human adult microglia: implication's for Alzheimer's disease. Brain Res. 951, 218-226 (2002).
41. Planas AM, Soriano MA, Rodriguez-Farr E et al. Induction of cyclooxygenase-2 mRNA and protein following focal ischaemia in the rat brain. Neuroscience Lett. 200, 187-190 (1995).
42. Aisen PS. Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease. J. Pain Symp. Manag. 23, S35-S40 (2002).
43. Aisen PS, Schafer KA, Grindman M et al. Effects of rofecoxib and naproxen vs. placebo on Alzheimer's disease progression. JAMA 289, 2819-2826 (2003).
44. Reines SA, Block GA, Morris JC et al. Rofecoxib. No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62, 66-71 (2004).
45. Ho L, Purohit D, Haroutunian V et al. Neuronal cyclooxygenase-2 expression in the hippocampal formation as a function of the clinical progression of Alzheiemr's disease. Arch. Neurol. 58, 487-492 (2001).
46. Blasko I, Apochal A, Boeck G et al. Ibuprofen decreases cytokine-induced amyloid β production in neuronal cells. Neurobiol. Dis. 8, 1094-1101 (2001).
47. Weggen S, Eriksen J, Das P et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414, 212-216 (2001).
48. Sastre M, Dewachter I, Landreth G et al. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-γ agonists modulate immunostimulated processing of amyloid precursor protein through regulation of γ-secretase. J. Neuroscience 23, 9796-9804 (2003).